SK Biopharm Targets KRW 700 Billion in Annual Sales on Strong Epilepsy Drug Growth
SK Biopharm has set its sights on surpassing KRW 700 billion (approximately $515 million) in annual sales this…
Xcopri
2 개의 기사가 있습니다.
"SK Biopharm's Epilepsy Drug Excels in the U.S."... Growth Expected in the Second Half
SK Biopharm is expected to continue its performance growth in the second half of the year, driven by…